Structure Therapeutics Reports Weight Loss Results for Oral GLP-1 Agonist Aleniglipron in Phase 2b Trial

Structure Therapeutics published data from its Phase 2b ACCESS clinical trial in the journal *Nature Medicine*, detailing the efficacy and safety profile of its oral GLP-1 receptor agonist, aleniglipron, for the treatment of obesity. The study reports that participants receiving the drug achieved statistically significant weight loss compared to those in the placebo group over the course of the trial.

The clinical trial evaluated the weight-reduction effects of daily oral doses of aleniglipron in adults with obesity or overweight conditions. Researchers monitored participants for changes in body weight, metabolic markers, and adverse events throughout the study period. The published findings indicate that the treatment group experienced a measurable reduction in body mass index, while the safety data showed a profile consistent with other therapies in the GLP-1 receptor agonist class. The company conducted this study to assess the potential of an oral small-molecule alternative to existing injectable obesity treatments.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 5, 2026

Author

GOAI